{"id":"cerdulatinib-0-37-gel","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Application site erythema"},{"rate":null,"effect":"Pruritus"}]},"_chembl":{"chemblId":"CHEMBL4116008","moleculeType":"Small molecule","molecularWeight":"445.55"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Cerdulatinib inhibits both Janus kinase 1 (JAK1) and spleen tyrosine kinase (SYK), which are key enzymes in the signaling cascades that drive T-cell and B-cell activation and inflammatory cytokine production. By blocking these kinases, the drug reduces the pathogenic immune response in inflammatory skin conditions. The topical gel formulation allows direct application to affected skin areas while minimizing systemic exposure.","oneSentence":"Cerdulatinib is a dual JAK1/SYK inhibitor that suppresses inflammatory signaling pathways in immune cells to reduce skin inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:50:40.709Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atopic dermatitis (topical)"},{"name":"Alopecia areata (topical)"}]},"trialDetails":[{"nctId":"NCT04103060","phase":"PHASE2","title":"Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo","status":"COMPLETED","sponsor":"Dermavant Sciences GmbH","startDate":"2019-09-27","conditions":"Vitiligo","enrollment":33}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DMVT-502"],"phase":"phase_2","status":"active","brandName":"Cerdulatinib 0.37% gel","genericName":"Cerdulatinib 0.37% gel","companyName":"Dermavant Sciences GmbH","companyId":"dermavant-sciences-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cerdulatinib is a dual JAK1/SYK inhibitor that suppresses inflammatory signaling pathways in immune cells to reduce skin inflammation. Used for Atopic dermatitis (topical), Alopecia areata (topical).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}